Lubiprostone, Colonic Motility and Sensation

This study has been completed.
Sponsor:
Collaborators:
Takeda
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00953043
First received: August 4, 2009
Last updated: February 23, 2012
Last verified: February 2012
  Purpose

This study is being done to evaluate the effects of lubiprostone, a drug approved and used for constipation, on pattern of contractions of the colon and the colon's sensitivity to distension.


Condition Intervention Phase
Healthy
Drug: lubiprostone
Drug: Placebo
Other: Bowel preparation
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Lubiprostone, a Chloride Channel Activator, on Colonic Sensorimotor Functions in Healthy Subjects. A Phase IV, Placebo-Controlled, Parallel Group Study

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Colonic Compliance [ Time Frame: 1 hour after third dose of lubiprostone or placebo, on Day 3 ] [ Designated as safety issue: No ]

    Colonic compliance is a measure of the "stiffness" of the colon, that is, what pressure was needed to reach half the maximum volume of the colon.

    After the barostat catheter was inserted in the colon, the catheter was connected to a barostat machine. After an initial conditioning distension to 20 mm Hg, colonic compliance was measured by step-wise inflation with increments of 4 mm Hg up to 64 mm Hg. Colonic compliance was analyzed by a validated linear interpolation method. The pressure at half maximum volume serves as a summary of colonic compliance.


  • Fasting Colonic Tone [ Time Frame: 30 minutes after the colonic tube placement, on Day 3 ] [ Designated as safety issue: No ]
    Colonic tone is a measurement of the volume of the colon. Colonic tone was assessed by noting the changes in the balloon volume in the presence of a constant operating pressure in the balloon (in the barostat-manometric assembly placed in the colon).

  • Postprandial Colonic Tone [ Time Frame: 30 minutes after standard meal, on Day 3 ] [ Designated as safety issue: No ]
    Colonic tone was assessed by noting the changes in the balloon volume in the presence of a constant operating pressure in the balloon (in the barostat-manometric assembly placed in the colon).

  • Pain Sensation Ratings in Response to Colonic Distension at 32 mm HG Above Baseline Operating Pressure [ Time Frame: approximately 1 hour after colonic tube placement, on Day 3 ] [ Designated as safety issue: Yes ]
    Pain was measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain.


Secondary Outcome Measures:
  • Gas Sensation Ratings in Response to Colonic Distensions at 32 mm Hg Above Baseline Operating Pressure [ Time Frame: approximately 1 hour after colonic tube placement, on Day 3 ] [ Designated as safety issue: No ]
    Gas sensation was measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no gas sensation and 100 mm for extreme gas sensation. The investigator measures the mark made by the participant in mm and records this for the value of gas sensation.

  • Median Pressure When First Sensation Was Reported by 50% of Participants [ Time Frame: approximately 45 min after colonic tube placement, on Day 3 ] [ Designated as safety issue: No ]
    The sensory threshold for first sensation was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mmg Hg. During this assessment participants were asked to report when they had the first sensation. The investigator recorded the threshold pressure at which the participants reported this sensation.

  • Median Pressure When Gas Sensation Was First Reported by 50% of Participants [ Time Frame: approximately 45 min after colonic tube placement, on Day 3 ] [ Designated as safety issue: No ]
    The sensory threshold for first perception of gas was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mmg Hg. During this assessment participants were asked to report when they had the first perception of gas. The investigator recorded the threshold pressure at which the participants reported this sensation.

  • Median Pressure When Pain Sensation Was First Reported by 50% of Participants [ Time Frame: approximately 45 min after colonic tube placement, on Day 3 ] [ Designated as safety issue: No ]
    The sensory threshold for first perception of pain was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mmg Hg. During this assessment participants were asked to report when they had the first perception of pain. The investigator recorded the threshold pressure at which the participants reported this sensation.


Enrollment: 60
Study Start Date: September 2007
Study Completion Date: July 2009
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Lubiprostone
Subjects randomized to this arm received 24 micrograms of lubiprostone per day for three days.
Drug: lubiprostone
Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
Other Name: Amitiza
Other: Bowel preparation
Polyethylene glycol-based bowel preparation
Other Name: NuLytely
Placebo Comparator: Placebo
Subjects randomized to this arm received placebo medication for three days.
Drug: Placebo
Placebo medication given for three days
Other: Bowel preparation
Polyethylene glycol-based bowel preparation
Other Name: NuLytely

Detailed Description:

This was a trial of healthy adults to compare the effects of oral lubiprostone, 24 microgram per day and placebo for three days, on sensation and contractions of the colon using validated methods.

On days 1 and 2, participants took the study medication with their breakfast and recorded the time. On day 2 starting at 4:00 pm, participants started a polyethylene glycol-based bowel preparation to cleanse the colon. After overnight bowl preparation, participants reported fasting to the study center at 7:00 am on day 3. Colonic sensorimotor functions were assessed by an endoscopically placed barostat-manometric assembly.

After 30 minutes of rest following tube placement, fasting colonic tone, colonic compliance and colonic sensation were tested. The last dose of medication was ingested and 1 hour later the same colonic functions, as well as colonic response to a standardized meal of a 1,000-kilocalorie chocolate milkshake were assessed. The participant was able to leave the study center in the afternoon, after a meal had been ingested (if desired).

Details on colonic tube placement: A flexible sigmoidoscopy was performed to evaluate the left side of the colon and to place a Teflon-coated guide wire beyond the splenic flexure. The colon was deflated as the sigmoidoscope was removed and a barostat catheter (constructed at Mayo Clinic, Rochester, MN) with six manometric point sensors and a polyethylene balloon was introduced into the colon over the guide wire. The barostat catheter was positioned in the mid-descending or upper sigmoid colon with the aid of fluoroscopy. The final position of the barostatically controlled balloon was confirmed by fluoroscopy. After the colonic tube placement, participants rested for 30 min. The catheter was connected to a rigid piston barostat machine. After transient inflation of the barostat bag to a volume of 75 ml to ensure it was unfolded, it was deflated. Thereafter, it was inflated in 2 mm Hg increments to baseline operating pressure, which was defined as 2 mm Hg above the minimal distension pressure at which respiratory excursions were clearly recorded by the barostat tracing.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Healthy subjects
  • Body mass index (BMI): 18 to 32.
  • Negative pregnancy test for women of childbearing potential.
  • Absence of gastrointestinal symptoms (abridged Bowel Disease Questionnaire).
  • Signed informed consent.

Exclusion criteria:

  • Subjects with body mass index (BMI) of less than 18 or more than 32.
  • Structural or metabolic diseases/conditions that affect the gastrointestinal (GI)system, or functional gastrointestinal disorders. For screening, the Bowel Disease Questionnaire will be used to exclude subjects with irritable bowel syndrome.
  • Use of drugs or agents within the past 2 weeks that alter GI transit including laxatives, magnesium or aluminum-containing antacids, prokinetics, erythromycin, narcotics, anticholinergics, tricyclic antidepressants, SSRI and newer antidepressants.

NOTE: Low stable doses of thyroid replacement, estrogen replacement, low dose aspirin for cardioprotection, and birth control pills or depot injections are permissible.

  • Use of drugs or agents within the 2 weeks prior to screening that may add drowsiness and central nervous system (CNS) depression such as barbiturates, benzodiazepines, ethanol, lithium, opioids, buspirone, antihistamines, muscle relaxants, other CNS depressants.
  • Female subjects who are pregnant or breast feeding.
  • Females must be either surgically sterilized, postmenopausal (>12 months since last menses) or, if of childbearing potential, using reliable methods of contraception as determined by the physician (single-barrier methods alone and rhythm methods are not acceptable).
  • Clinical evidence (including physical exam and ECG) of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurological, psychiatric, or other disease that interfere with the objectives of the study. Any candidate participants with such disorder mentioned will be referred to their general physician.
  • The Hospital Anxiety and Depression Scale (HADS) will be used to exclude subjects with significant affective disorders, as well as to determine anxiety and depression scores at the start of the study. Any candidate participants with such disorder mentioned will be referred to their general physician.
  • Symptoms of a significant clinical illness in the two weeks prior to screening.
  • Participation in another clinical study within the 30 days prior to screening.
  • Subjects who are considered by the investigator to be alcoholics not in remission or known substance abusers.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00953043

Locations
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Takeda
Investigators
Principal Investigator: Michael Camilleri, MD Mayo Clinic
  More Information

Additional Information:
Publications:
Responsible Party: Michael Camilleri, Mayo Clinic
ClinicalTrials.gov Identifier: NCT00953043     History of Changes
Other Study ID Numbers: 07-001438, K24DK002638, R01DK054681, UL1RR024150
Study First Received: August 4, 2009
Results First Received: January 9, 2012
Last Updated: February 23, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Mayo Clinic:
lubiprostone
colon
motility
sensation

ClinicalTrials.gov processed this record on October 23, 2014